newsfilter
← Latest News
GlobeNewswire·

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated during 1H 2023 – – Presented preclinical data showing